Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 (durvalumab) in combination with olaparib ± bevacizumab in advanced solid tumors
2015-004005-16Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Dec 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in ovarian cancer and advanced nonhematological malignancy (2 arms), sponsored by AstraZeneca. Primary endpoint: Disease control rate (DCR). Status: unknown.
02
Drugs
durvalumab
03
Conditions
ovarian canceradvanced nonhematological malignancy
Beyond the preview
Go deeper on 2015-004005-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004005-16.